Glenmark Pharmaceuticals has entered into an agreement with Triax and Astellas to resolve a patent infringement case in the US over its generic hydrocortisone butyrate cream, used for the treatment of skin infections. The suit is related to Glenmark's filing of an abbreviated new drug application (ANDA) for 0.1% hydrocortisone butyrate cream. Hydrocortisone butyrate cream is a generic version of Triax's Locoid Lipocream.

Under the settlement and licence pact, Glenmark will be permitted to market and distribute its 0.1% hydrocortisone butyrate cream under a royalty-bearing licence from Astellas and Triax in the US near the end of 2013. Glenmark is entitled to 180 days exclusivity with respect to its cream, as it was first to file an ANDA for the product. The IMS Health data, indicates that Locoid Lipocream achieved sales of nearly $38 million in 2010.crackcrack

Glenmark Pharma Share Price

1178.00 17.25 (1.49%)
03-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1453.25
Dr. Reddys Lab 5792.95
Cipla 1459.85
Zydus Lifesciences 1032.25
Lupin 1583.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.